These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35185008)

  • 1. Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients.
    Te Kampe R; Boonen A; Jansen T; Janssen M; de Vries H; van Durme C
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35185008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cohort study investigating gout flares and management in UK general practice.
    Finnikin S; Mallen CD; Roddy E
    BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
    Zhang X; Tang Y; Wang M; Wang D; Li Q
    Clin Rheumatol; 2021 Feb; 40(2):701-710. PubMed ID: 32562072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout.
    Te Kampe R; Boonen A; Jansen TL; Elling JM; Flendrie M; van Eijk-Hustings Y; Janssen M; van Durme C; de Vries H
    BMC Med Inform Decis Mak; 2022 Apr; 22(1):95. PubMed ID: 35392890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
    Singh JA
    Arthritis Res Ther; 2014 Mar; 16(2):R82. PubMed ID: 24678765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
    Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
    Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
    Latif ZP; Nakafero G; Jenkins W; Doherty M; Abhishek A
    Joint Bone Spine; 2019 May; 86(3):357-362. PubMed ID: 30394337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
    Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
    Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
    Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
    Peeters IR; den Broeder AA; Taylor WJ; den Broeder N; Flendrie M; van Herwaarden N
    Trials; 2023 Apr; 24(1):282. PubMed ID: 37072799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence.
    Chung MK; Kim SS; Cheon YH; Hong SJ; Choi HJ; Seo MR; Hwang J; Ahn JK; Lee SH; Min HK; Cha HS; Lee SS; Lee J; Moon KW; Lee CK; Kim HO; Suh YS; Shim SC; Kang SW; Kim J; Choi ST; Song JS; Lee J;
    J Korean Med Sci; 2021 Aug; 36(32):e208. PubMed ID: 34402226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
    Latourte A; Bardin T; Richette P
    Rheumatology (Oxford); 2014 Nov; 53(11):1920-6. PubMed ID: 24758886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.